Daratumumab plus Lenalidomide/ dexamethasone in transplant-neligible patients with newly diagnosed multiple myeloma: MAIA update

被引：0

作者：

Basu, Supratik ^{[1
]}

Kumar, Shaji K. ^{[2
]}

Moreau, Philippe ^{[3
]}

Bahlis, Nizar ^{[4
]}

Facon, Thierry ^{[5
]}

Plesner, Torben ^{[6
,7
]}

Orlowski, Robert Z. ^{[8
]}

Nahi, Hareth ^{[9
]}

Hulin, Cyrille ^{[10
]}

Quach, Hang ^{[11
]}

Goldschmidt, Hartmut ^{[12
]}

O'Dwyer, Michael ^{[13
]}

Perrot, Aurore ^{[14
]}

Venner, Christopher P. ^{[15
]}

Weisel, Katja ^{[16
]}

Raje, Noopur ^{[17
]}

Tiab, Mourad ^{[18
]}

Macro, Margaret ^{[19
]}

Frenzel, Laurent ^{[20
]}

Leleu, Xavier ^{[21
]}

Pei, Huiling ^{[22
]}

Krevvata, Maria ^{[23
]}

Borgsten, Fredrik ^{[24
]}

Usmani, Saad Z. ^{[25
]}

机构：

[1] Royal Hosp Wolverhampton, Wolverhampton, England

[2] Mayo Clin Rochester, Dept Haematol, Rochester, MN USA

[3] Univ Hosp Hotel Dieu, Dept Hematol, Nantes, France

[4] Univ Calgary, Arnie Charbonneau Canc Res Inst, Calgary, AB, Canada

[5] Univ Lille, CHU Lille, Serv Malad Sang, Lille, France

[6] Vejle Hosp, Vejle, Denmark

[7] Univ Southern Denmark, Vejle, Denmark

[8] Univ Texas MD Anderson Canc Ctr, Dept Lymphoma & Myeloma, Houston, TX USA

[9] Karolinska Inst, Karolinska Univ Hosp Huddinge, Div Haematol, Dept Med, Stockholm, Sweden

[10] Univ Hosp Pessac, Dept Haematol, Hop Haut Leveque, Pessac, France

[11] Univ Melbourne, St Vincents Hosp, Melbourne, Australia

[12] Univ Heidelberg Hosp, GMMG Study Grp, Internal Med 5, Heidelberg, Germany

[13] NUI, Dept Med Haematol, Galway, Ireland

[14] UPS, Univ Toulouse, CHU Toulouse, IUCT O,Serv Hematol, Toulouse, France

[15] Univ Alberta, Cross Canc Inst, Dept Med Oncol, Edmonton, AB, Canada

[16] Univ Med Ctr Hamburg Eppendorf, Haematol & Bone Marrow Transplantat Sect Pneumol, Dept Oncol, Hamburg, Germany

[17] Massachusetts Gen Hosp, Ctr Multiple Myeloma, Canc Ctr, Boston, MA USA

[18] CHD Vendee, La Roche Sur Yon, France

[19] Ctr Hosp Univ CHU Caen, Caen, France

[20] Hop Necker Enfants Malad, Paris, France

[21] Hop Miletrie, CHU Poitiers, Poitiers, France

[22] Janssen Res & Dev LLC, Titusville, NJ USA

[23] Janssen Res & Dev LLC, Spring House, PA USA

[24] Janssen Res & Dev LLC, Raritan, NJ USA

[25] Mem Sloan Kettering Canc Ctr, New York, NY USA

来源：

BRITISH JOURNAL OF HAEMATOLOGY | 2023年 / 201卷

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

BSH23-OR21

引用

页码：17 / 18

页数：2

共 50 条

[1] Daratumumab Plus Lenalidomide and Dexamethasone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma: Maia Age Subgroup Analysis
Facon, Thierry
Kumar, Shaji K.
Weisel, Katja
Usmani, Saad
Moreau, Philippe
Plesner, Torben
Orlowski, Robert Z.
Bahlis, Nizar Jacques
Basu, Supratik
Nahi, Hareth
Hulin, Cyrille
Quach, Hang
O'Dwyer, Michael
Perrot, Aurore
Venner, Christopher P.
Raje, Noopur
Tiab, Mourad
Macro, Margaret
Frenzel, Laurent
Leleu, Xavier
Pei, Huiling
Carson, Robin
Borgsten, Fredrik
Goldschmidt, Hartmut
BLOOD, 2022, 140 : 10133 - 10136
[2] Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA
Thierry Facon
Gordon Cook
Saad Z. Usmani
Cyrille Hulin
Shaji Kumar
Torben Plesner
Cyrille Touzeau
Nizar J. Bahlis
Supratik Basu
Hareth Nahi
Hartmut Goldschmidt
Hang Quach
Mohamad Mohty
Christopher P. Venner
Katja Weisel
Noopur Raje
Benjamin Hebraud
Karim Belhadj-Merzoug
Lotfi Benboubker
Olivier Decaux
Salomon Manier
Denis Caillot
Jon Ukropec
Huiling Pei
Rian Van Rampelbergh
Clarissa M. Uhlar
Rachel Kobos
Sonja Zweegman
Leukemia, 2022, 36 : 1066 - 1077
[3] Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA
Facon, Thierry
Cook, Gordon
Usmani, Saad Z.
Hulin, Cyrille
Kumar, Shaji
Plesner, Torben
Touzeau, Cyrille
Bahlis, Nizar J.
Basu, Supratik
Nahi, Hareth
Goldschmidt, Hartmut
Quach, Hang
Mohty, Mohamad
Venner, Christopher P.
Weisel, Katja
Raje, Noopur
Hebraud, Benjamin
Belhadj-Merzoug, Karim
Benboubker, Lotfi
Decaux, Olivier
Manier, Salomon
Caillot, Denis
Ukropec, Jon
Pei, Huiling
Van Rampelbergh, Rian
Uhlar, Clarissa M.
Kobos, Rachel
Zweegman, Sonja
LEUKEMIA, 2022, 36 (04) : 1066 - 1077
[4] Daratumumab Plus Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma
Jakubowiak, Andrzej
Usmani, Saad Z.
Krishnan, Amrita
Lonial, Sagar
Comenzo, Raymond L.
Wang, Jianping
de Boer, Carla
Deraedt, William
Weiss, Brendan M.
Schecter, Jordan M.
Chari, Ajai
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2021, 21 (10) : 701 - 710
[5] Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant: Updated Analysis of Maia
Bahlis, Nizar
Facon, Thierry
Usmani, Saad Z.
Kumar, Shaji K.
Plesner, Torben
Orlowski, Robert Z.
Touzeau, Cyrille
Basu, Supratik
Nahi, Hareth
Hulin, Cyrille
Quach, Hang
Goldschmidt, Hartmut
O'Dwyer, Michael E.
Venner, Christopher P.
Weisel, Katja C.
Krevvata, Maria
Pei, Huiling
Wang, Jianping
Van Rampelbergh, Rian
Ukropec, Jon
Uhlar, Clarissa M.
Kobos, Rachel
Perrot, Aurore
BLOOD, 2019, 134
[6] Plain language summary of the MAIA study of daratumumab plus lenalidomide and dexamethasone for the treatment of people with newly diagnosed multiple myeloma
Facon, Thierry
Kumar, Shaji K.
Plesner, Torben
Orlowski, Robert Z.
Moreau, Philippe
Bahlis, Nizar
Basu, Supratik
Nahi, Hareth
Hulin, Cyrille
Quach, Hang
Goldschmidt, Hartmut
Perrot, Aurore
Weisel, Katja
Raje, Noopur
Macro, Margaret
Frenzel, Laurent
Leleu, Xavier
Wang, Jianping
Van Rampelbergh, Rian
Uhlar, Clarissa M.
Vermeulen, Jessica
Duran, Joana
Borgsten, Fredrik
Usmani, Saad Z.
FUTURE ONCOLOGY, 2023, 19 (13) : 887 - 895
[7] Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA)
Facon, Thierry
Kumar, Shaji K.
Plesner, Torben
Orlowski, Robert Z.
Moreau, Philippe
Bahlis, Nizar
Basu, Supratik
Nahi, Hareth
Hulin, Cyrille
Quach, Hang
Goldschmidt, Hartmut
O'Dwyer, Michael
Perrot, Aurore
Venner, Christopher P.
Weisel, Katja
Mace, Joseph R.
Ahmadi, Tahamtan
Chiu, Christopher
Wang, Jianping
Van Rampelbergh, Rian
Uhlar, Clarissa M.
Kobos, Rachel
Qi, Ming
Usmani, Saad Z.
BLOOD, 2018, 132
[8] Phase 3 randomized study of Daratumumab plus lenalidomide and Dexamethasone (D-Rd) versus lenalidomide and Dexamethasone (Rd) in patients with newly diagnosed multiple myeloma (NDMM) ineligible for transplant (MAIA)
Weisel, K.
Facon, T.
Kumar, S.
Plesner, T.
Orlowski, R. Z.
Moreau, P.
Bahlis, N.
Basu, S.
Nahi, H.
Hulin, C.
Quach, H.
Goldschmidt, H.
O'Dwyer, M.
Perrot, A.
Venner, C. P.
Mace, J. R.
Ahmadi, T.
Chiu, C.
Wang, J.
van Rampelbergh, R.
Uhlar, C. M.
Kobos, R.
Qi, M.
Usmani, S. Z.
ONCOLOGY RESEARCH AND TREATMENT, 2019, 42 : 194 - 194
[9] Daratumumab plus lenalidomide/bortezomib/dexamethasone in Black patients with transplant-eligible newly diagnosed multiple myeloma in GRIFFIN
Nooka, Ajay K.
Kaufman, Jonathan L.
Rodriguez, Cesar
Jakubowiak, Andrzej
Efebera, Yvonne
Reeves, Brandi
Wildes, Tanya
Holstein, Sarah A.
Anderson, Larry D., Jr.
Badros, Ashraf
Shune, Leyla
Chari, Ajai
Pei, Huiling
Cortoos, Annelore
Patel, Sharmila
Bartlett, J. Blake
Vermeulen, Jessica
Lin, Thomas S.
Richardson, Paul G.
Voorhees, Peter
BLOOD CANCER JOURNAL, 2022, 12 (04)
[10] Carfilzomib, lenalidomide, and dexamethasone plus transplant in newly diagnosed multiple myeloma
Jasielec, Jagoda K.
Kubicki, Tadeusz
Raje, Noopur
Vij, Ravi
Reece, Donna
Berdeja, Jesus
Derman, Benjamin A.
Rosenbaum, Cara A.
Richardson, Paul
Gurbuxani, Sandeep
Major, Sarah
Wolfe, Brittany
Stefka, Andrew T.
Stephens, Leonor
Tinari, Kathryn M.
Hycner, Tyler
Rojek, Alexandra E.
Dytfeld, Dominik
Griffith, Kent A.
Zimmerman, Todd M.
Jakubowiak, Andrzej J.
BLOOD, 2020, 136 (22) : 2513 - 2523

← 1 2 3 4 5 →